Evaluating Tozorakimab for Patients with Viral Lung Infections Needing Oxygen

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the efficacy and safety of tozorakimab, an investigational drug, as an additional treatment for adults hospitalized with viral lung infections who require supplemental oxygen. The study will compare the effects of tozorakimab against a placebo to determine its impact on preventing death or the need for invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Participants must be experiencing hypoxaemia and meet specific criteria related to their respiratory condition. The trial is designed to provide insights into the potential benefits of tozorakimab in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult participants ≥ 18 years old at the time of signing the informed consent form.
* Patients hospitalised with viral lung infection.
* Hypoxaemia requiring treatment with supplemental O2.

Hypoxaemia is defined as:

SpO2 ≤ 90% OR

SpO2 ≤ 92% AND one or both of the following:

Radiographic infiltrates by CXR/CT compatible with viral lung infection per investigator judgement.

Use of accessory muscles of respiration or RR (respiratory rate) \> 22.

\- Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen.

Exclusion Criteria:

* Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition.
* Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.
* Ongoing IMV/ECMO at randomisation.

Where it's running

• Research Site
  Mobile, Alabama, United States Recruiting
• Research Site
  Tucson, Arizona, United States Recruiting
• Research Site
  Fresno, California, United States Recruiting
• Research Site
  Newport Beach, California, United States Recruiting
• Research Site
  Torrance, California, United States Recruiting
• Research Site
  Colorado Springs, Colorado, United States Recruiting

+423 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety of Tozorakimab in COPD patients with prior exacerbations

  This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.

  Recruiting at 5 sites Phase 3 AstraZeneca · Aix-en-Provence and 12 other locations · NCT07566195

• Assessing the effects of tozorakimab in adults with uncontrolled asthma

  This study is testing a new asthma treatment called tozorakimab to see if it can help adults who still have asthma problems despite using their current medications.

  Recruiting at 144 sites Phase 2 AstraZeneca · Bakersfield, California and 222 other locations · NCT06932263

• Different doses of Ingavirin Forte capsules for adults with influenza or other acute respiratory infections.

  This trial will see if different doses of Ingavirin Forte capsules help adults (18–65) with PCR-confirmed influenza or other acute respiratory viral infections.

  Recruiting at 11 sites Phase 2 Valenta Pharm JSC · Ivanovo and 10 other locations · NCT07420985

• Efficacy and safety of Raphamin for treating respiratory infections in children

  This study is testing if a new medicine called Raphamin can help children aged 3 to 12 with respiratory infections feel better and recover faster.

  Recruiting at 28 sites Phase 3 Materia Medica Holding · Gatchina and 34 other locations · NCT06715891

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.